New 52 Week Low Today

Neximmune Inc NEXI:NASDAQ

RT Quote | NASDAQ | USD
Last | 4:00 PM EST
0.3476quote price arrow down-0.0068 (-1.9187%)
Volume
73,067
52 week range
0.34 - 6.58
Loading...
  • Open0.3667
  • Day High0.3799
  • Day Low0.34
  • Prev Close0.3544
  • 52 Week High6.58
  • 52 Week High Date12/09/21
  • 52 Week Low0.34
  • 52 Week Low Date12/09/22

Key Stats

  • Market Cap9.07M
  • Shares Out26.08M
  • 10 Day Average Volume0.09M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-92.46

KEY STATS

  • Open0.3667
  • Day High0.3799
  • Day Low0.34
  • Prev Close0.3544
  • 52 Week High6.58
  • 52 Week High Date12/09/21
  • 52 Week Low0.34
  • 52 Week Low Date12/09/22
  • Market Cap9.07M
  • Shares Out26.08M
  • 10 Day Average Volume0.09M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-92.46

RATIOS/PROFITABILITY

  • EPS (TTM)-2.64
  • P/E (TTM)-0.13
  • Fwd P/E (NTM)-0.16
  • EBITDA (TTM)-60.402M
  • ROE (TTM)-84.43%
  • Revenue (TTM)0.00
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date03/07/2023(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Neximmune Inc

 

Profile

MORE
NexImmune, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing an approach to immunotherapy designed to employ the body’s own T cells to generate an immune response that mimics natural biology. Its product candidates include NEXI-001 in acute myeloid leukemia (AML) and NEXI-002 in multiple myeloma (MM). The Company provides Artificial Immune Modulation (AIM), which is a nanoparticle technology platform. Its AIM technology enables it to...
Sol Barer Ph.D.
Independent Chairman of the Board
Kristi Jones
President, Chief Executive Officer, Director